As pharmaceutical and healthcare organizations
prepare to edge back to something resembling normality within the time of
COVID-19, the risks around travel need to be assessed (given the relative ease
of infectivity of the SARS-CoV-2 virus). There will be visits required to
conduct Factory Acceptance Tests, to review contract laboratory facilities, to
review new technologies and so on. A foremost concern should be with ensuring
that the measures taken on-site are applied to the travelling employee. An
effective way to achieve this is through a risk assessment. The key criterion
should be with travel, accommodation, site visits and return to work. This is
after the question ‘Is the travel really necessary?’ has been posed and
satisfactorily answered.
Pharmaceutical and healthcare organizations have been
grappling with the novel coronavirus throughout 2020 (the starting point varies
depending on the country, although on 11th February 2020 the World Health
Organization declared a pandemic and officially named the disease caused by the
SARS-CoV02 virus as COVID-19, short for “coronavirus disease 2019.”
In response of the vectors of transmission, the
hierarchy of protective measures is:
Do not visit.
Maintain social distancing (at 2 meters or greater).
Sanitize hands regularly.
Wear appropriate PPE, including surgical facemasks.
This article outlines advice for employers and
employees working in pharmaceuticals and healthcare in relation to key business
travel.
The reference is:
Free access at: https://www.ivtnetwork.com/article/time-travel-looking-risks-covid-19-era
Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)
No comments:
Post a Comment
Pharmaceutical Microbiology Resources